Modulation of Erythrocyte Mobility Using Magnetite Nanoparticles: A Nanomedical Perspective for Critical Care and Transfusion Therapy

Andrey Belousov

Kharkiv National Medical University, Ukraine

Biography :

Andrey N. Belousov, MD, PhD, Professor - a Ukrainian medical scientist and pioneer in nano­technology, who developed the world’s first biocompatible nano­medical drugs (Micromage-B, MCS-B, ICNB), officially regis­tered and introduced into clinical practice since 1998. His work es­tablished a translational founda­tion for medical nanotechnology, linking fundamental biophysics with clinical applications in de­toxification, hemocorrection, and neuroprotection. The published more 360 scientific works on re­sults application of nanotechnol­ogy preparation in experimental and practical medicine. At now Andrey Belousov - the Head of Laboratory Applied Nanotech­nologies, Professor of Kharkiv Na­tional Medical University, Ukraine.

Abstract :

A decrease in erythrocyte electrophoretic mobility serves as an important diagnostic marker of pathological conditions associated with impaired gas exchange, microcirculation, and tissue trophism, often leading to systemic hypoxia and deterioration of the patient’s clinical status. This study inves­tigates the potential of magnetite nanoparticles (MCS-B) to modulate these properties in a targeted and controlled man­ner. A novel approach is proposed to enhance erythrocyte electrophoretic mobility in patients with toxemia through treatment with magnetite nanoparticles. In vitro experiments demonstrated a statistically significant (p < 0.001) increase - nearly threefold - in erythrocyte mobility following exposure to MCS-B, compared to untreated controls. The optimal ef­ficacy was observed at a blood-to-nanoparticle ratio of 2:1. Furthermore, application of a constant magnetic field with an intensity of 200–250 kA/m for 2-3 minutes resulted in ef­fective removal of residual nanoparticles from blood sam­ples (p < 0.001). The results highlight the biocompatibility and clinical potential of this nanomedical approach, which may serve as a basis for new therapeutic strategies in transfusion medicine, critical care, and regenerative therapy. The study addresses a pressing interdisciplinary challenge, bridging hematology, biophysics, and nanotechnology, with implica­tions for both basic science and clinical implementation.